A phase IIb study assessing PAX-101 for Autism Spectrum Disorder
Latest Information Update: 05 Sep 2023
At a glance
- Drugs Suramin sodium (Primary)
- Indications Pervasive child development disorders
- Focus Therapeutic Use
- Sponsors PaxMedica
- 05 Sep 2023 Status changed from recruiting to completed as per Paxmedica company pipeline.
- 19 Aug 2021 According to a PaxMedica media release, company recently completed a pre-IND meeting with FDA to review the results of this trial as a first step toward conducting US clinical trials with PAX-101 in the near future.
- 19 Aug 2021 According to a PaxMedica media release, David Hough will present trial results at the upcoming AACAP Annual Meeting during the Research Pipeline: New Findings on Diagnostics and Therapeutics program.